AMAG Pharmaceuticals, Inc.
MarketLine (a Datamonitor Company)
02 Sep 2014
Available for Immediate Download
AMAG Pharmaceuticals, Inc. - Company Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, product and service offerings, and corporate actions, providing a 360° view of the company. Features: - Detailed information on AMAG Pharmaceuticals, Inc. required for business and competitor intelligence needs - Intelligence on AMAG Pharmaceuticals, Inc.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about AMAG Pharmaceuticals, Inc., such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: AMAG Pharmaceuticals (AMAG) is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia in adult patients with chronic kidney disease (CKD). The company operates in the US and the UK. It is headquartered in Lexington, Massachusetts and employs around 129 people. The company recorded revenues of $85.4 million in the fiscal year ended December 2012, an increase of 39.4% over 2011. The company's operating loss was $17.4 million in fiscal 2012, as compared to an operating loss of $79.8 million in 2011. Its net loss was $16.8 million in fiscal 2012, as compared to the net loss of $77.1 million in 2011. Reasons to Purchase: - Gain understanding of AMAG Pharmaceuticals, Inc. the company and its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess AMAG Pharmaceuticals, Inc. as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on AMAG Pharmaceuticals, Inc. your competitors' business structure, strategy and prospects